Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
AKTSIASELTSI TALLINNA VESI (registrikood 10257326, aadress Ädala 10, 10614 Tallinn) (edaspidi ka Selts) juhatus teatab, et Seltsi aktsionäride korraline üldkoosolek toimub neljapäeval, 23. aprillil...
-
The Management Board of AS TALLINNA VESI (registry code 10257326, Ädala 10, 10614 Tallinn) (hereafter also referred to as ‘the Company’) announces that the Annual General Meeting of Shareholders of...
-
MONTREAL, March 30, 2026 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis” or “the Company”) (TSX:PYR) (OTCQX:PYRGF) (FRA:8PY1), a leader in ultra-high temperature processes & engineering...
-
HSINCHU, Taiwan, March 30, 2026 (GLOBE NEWSWIRE) -- AI is taking shape through display interfaces, where people see and interact in real-world settings. Micro LED is a key display engine that helps...
-
Commercial inflection with >$50 million in bookings in early 2026 Operating companies advancing independent capital formation, materially reducing reliance on Innventure’s balance sheet ...
-
New York City, NY, March 30, 2026 (GLOBE NEWSWIRE) -- Trying out a no deposit bonus casino is a simple way for new players to get a feel for online gaming without having to spend any money...
-
Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the...
-
Data showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal...
-
Le médicament biosimilaire de Teva, PONLIMSI™, est désormais approuvé par la FDA pour toutes les indications du produit de référence, Prolia® (dénosumab), dans le cadre du traitement de diverses...
-
Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.Teva’s proposed biosimilar...